Literature DB >> 20547518

Safety of triptans for migraine headaches during pregnancy and breastfeeding.

Silvia Duong1, Pina Bozzo, Hedvig Nordeng, Adrienne Einarson.   

Abstract

QUESTION: A patient who just found out that she is pregnant and suffers from migraine headaches informs me that she has been taking naratriptan. She indicates that she is planning on breastfeeding her baby and might need to continue treatment. How safe are the medications from this class of drugs during pregnancy and breastfeeding? ANSWER: Accumulated data suggest that exposure to sumatriptan during pregnancy does not increase the risk of birth defects above the baseline rate. There are currently insufficient data to confirm the safety of other triptans; however, evidence to date is reassuring. Information regarding safety of triptans while breastfeeding is limited but also reassuring, as the minimal amounts excreted into the milk are insufficient to cause any adverse effects on the breastfeeding infant.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20547518      PMCID： PMC2902939     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN： 0008-350X            Impact factor:   3.275


  17 in total

1.  Exposure to rizatriptan during pregnancy: post-marketing experience up to 30 June 2004.

Authors:  M Fiore; K E Shields; N Santanello; M R Goldberg
Journal:  Cephalalgia       Date:  2005-09       Impact factor: 6.292

Review 2.  Migraine during pregnancy: options for therapy.

Authors:  Anthony W Fox; Merle L Diamond; Egilius L H Spierings
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

3.  Treating pain during pregnancy.

Authors:  Malaika Babb; Gideon Koren; Adrienne Einarson
Journal:  Can Fam Physician       Date:  2010-01       Impact factor: 3.275

4.  Pregnancy outcome following first trimester exposure to sumatriptan.

Authors:  S Shuhaiber; A Pastuszak; B Schick; D Matsui; G Spivey; J Brochu; G Koren
Journal:  Neurology       Date:  1998-08       Impact factor: 9.910

5.  Pregnancy and perinatal outcomes in migraineurs using sumatriptan: a prospective study.

Authors:  S O'Quinn; S A Ephross; V Williams; R L Davis; D L Gutterman; A W Fox
Journal:  Arch Gynecol Obstet       Date:  1999-11       Impact factor: 2.344

6.  Triptan exposure during pregnancy and the risk of major congenital malformations and adverse pregnancy outcomes: results from the Norwegian Mother and Child Cohort Study.

Authors:  Katerina Nezvalová-Henriksen; Olav Spigset; Hedvig Nordeng
Journal:  Headache       Date:  2010-01-28       Impact factor: 5.887

7.  Use of 5-HT1 agonists in pregnancy.

Authors:  Emily W Evans; Kristin C Lorber
Journal:  Ann Pharmacother       Date:  2008-03-18       Impact factor: 3.154

Review 8.  Headache and pregnancy.

Authors:  Rukmini Menon; Cheryl D Bushnell
Journal:  Neurologist       Date:  2008-03       Impact factor: 1.398

9.  Acetaminophen use during pregnancy: effects on risk for congenital abnormalities.

Authors:  Cristina Rebordosa; Manolis Kogevinas; Erzsébet Horváth-Puhó; Bente Nørgård; Maria Morales; Andrew E Czeizel; Hendrik Vilstrup; Henrik T Sørensen; Jørn Olsen
Journal:  Am J Obstet Gynecol       Date:  2008-02       Impact factor: 8.661

Review 10.  Triptans in pregnancy.

Authors:  Offie P Soldin; Julia Dahlin; Daniel M O'Mara
Journal:  Ther Drug Monit       Date:  2008-02       Impact factor: 3.681
View more
  8 in total

Review 1.  Breastfeeding and migraine drugs.

Authors:  Riccardo Davanzo; Jenny Bua; Giulia Paloni; Giulia Facchina
Journal:  Eur J Clin Pharmacol       Date:  2014-09-13       Impact factor: 2.953

2.  Prenatal triptan exposure and parent-reported early childhood neurodevelopmental outcomes: an application of propensity score calibration to adjust for unmeasured confounding by migraine severity.

Authors:  Mollie E Wood; Jean A Frazier; Hedvig M E Nordeng; Kate L Lapane
Journal:  Pharmacoepidemiol Drug Saf       Date:  2015-11-11       Impact factor: 2.890

Review 3.  Non-invasive neuromodulation in the acute treatment of migraine: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Oliver Clark; Areej Mahjoub; Nily Osman; Ann-Marie Surmava; Saber Jan; Ana Marissa Lagman-Bartolome
Journal:  Neurol Sci       Date:  2021-10-26       Impact factor: 3.307

4.  Perinatal use of triptans and other drugs for migraine-A nationwide drug utilization study.

Authors:  Fatima Tauqeer; Mollie Wood; Sarah Hjorth; Angela Lupattelli; Hedvig Nordeng
Journal:  PLoS One       Date:  2021-08-23       Impact factor: 3.240

5.  Italian guidelines for primary headaches: 2012 revised version.

Authors:  Paola Sarchielli; Franco Granella; Maria Pia Prudenzano; Luigi Alberto Pini; Vincenzo Guidetti; Giorgio Bono; Lorenzo Pinessi; Massimo Alessandri; Fabio Antonaci; Marcello Fanciullacci; Anna Ferrari; Mario Guazzelli; Giuseppe Nappi; Grazia Sances; Giorgio Sandrini; Lidia Savi; Cristina Tassorelli; Giorgio Zanchin
Journal:  J Headache Pain       Date:  2012-05       Impact factor: 7.277

6.  Longitudinal changes in neurodevelopmental outcomes between 18 and 36 months in children with prenatal triptan exposure: findings from the Norwegian Mother and Child Cohort Study.

Authors:  Mollie E Wood; Jean A Frazier; Hedvig M E Nordeng; Kate L Lapane
Journal:  BMJ Open       Date:  2016-09-13       Impact factor: 2.692

Review 7.  Headache and pregnancy: a systematic review.

Authors:  A Negro; Z Delaruelle; T A Ivanova; S Khan; R Ornello; B Raffaelli; A Terrin; U Reuter; D D Mitsikostas
Journal:  J Headache Pain       Date:  2017-10-19       Impact factor: 7.277

Review 8.  Chronic pain during pregnancy: a review of the literature.

Authors:  Shona L Ray-Griffith; Michael P Wendel; Zachary N Stowe; Everett F Magann
Journal:  Int J Womens Health       Date:  2018-04-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.